Evidence map›Paper›PMID 28860340›Full record

ArticleHaematologica2017

Impact of hospital experience on the quality of tyrosine kinase inhibitor response monitoring and consequence for chronic myeloid leukemia patient survival.

Inge G P Geelen, Noortje Thielen, Jeroen J W M Janssen, Mels Hoogendoorn, Tanja J A Roosma, Sten P Willemsen, Peter J M Valk, Otto Visser, Jan J Cornelissen, Peter E Westerweel

Abstract readLetterMulticenter Study
In one paragraph

Article in Haematologica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Chronic Myeloid Leukemia: Long-Term Outcome Data in the Imatinib Era.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Inge G P GeelenDepartment of Hematology, Albert Schweitzer Hospital, Dordrecht, the Netherlands.
Noortje ThielenDepartment of Hematology, VU University Medical Center, Amsterdam, the Netherlands.
Jeroen J W M JanssenDepartment of Hematology, VU University Medical Center, Amsterdam, the Netherlands.
Mels HoogendoornDepartment of Hematology, Medical Center Leeuwarden, Dordrecht, the Netherlands.
Tanja J A RoosmaDepartment of Hematology, VU University Medical Center, Amsterdam, the Netherlands.
Sten P WillemsenDepartment of Biostatistics, Albert Schweitzer Hospital, Dordrecht, the Netherlands.
Peter J M ValkDepartment of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Otto VisserNetherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands.
Jan J CornelissenDepartment of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Peter E WesterweelDepartment of Hematology, Albert Schweitzer Hospital, Dordrecht, the Netherlands p.e.westerweel@asz.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedAged, 80 and overDrug MonitoringHospitalsHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMiddle AgedNetherlandsProtein Kinase InhibitorsProtein-Tyrosine KinasesProtein Kinase InhibitorsProtein-Tyrosine Kinases

Identifiers

PMID28860340
PMCPMC5709118

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.